SCHEMBL12737463

SCHEMBL12737463

CCCc1ccc(-c2ccc(OC(=O)c3ccc(-c4ccc(C)c(F)c4F)cc3)c(F)c2F)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRB P10828 3/20 0.42
MAPT P10636 3/20 0.42
RARB P10826 3/20 0.41
MPL P40238 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
PLK1 P53350 1/20 0.37
NR2F2 P24468 1/20 0.36
PAX8 Q06710 1/20 0.36
KLF5 Q13887 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CYP4A11 Q02928 1/20 0.35
PTPN1 P18031 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12742636 1.00 THRB (0.42) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL17772281 0.91 THRB (0.42) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL12718255 0.90 RARB (0.42) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL12737477 0.89 MAPT (0.48) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL12742652 0.89 MAPT (0.48) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL12742640 0.88 THRB (0.42) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL12737466 0.88 THRB (0.42) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL3268316 0.87 RARB (0.53) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL12717963 0.86 RARB (0.47) THRBMAPTRARBMPLSMN1; SMN2
SCHEMBL12717875 0.86 RARB (0.49) THRBMAPTRARBMPLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394294-B2 Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2013-03-12 US disclosed
US-8394294-B2 Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2013-03-12 US disclosed
US-20110090450-A1 FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2011-04-21 US disclosed
US-20110090450-A1 FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2011-04-21 US disclosed
WO-2009150966-A1 TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT チッソ株式会社 (JP) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110090450-A1 FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE LEF1, LAS1L, EFHD2 THRB 2847/4885MAPT 1075/4885RARB 2705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.